https://www.selleckchem.com/pr....oducts/Temsirolimus.
Regarding clinicopathologcial features; older patients ( 65) were more likely to express PD-L1 (1 %) and IDO-1 (20 %). For tumor size, IDO-1 expression (5 %), along with PD-1/IDO-1 Co-expression (1/5 %), was associated with larger tumor size (5cm). For myometrial invasion, CSs with 50 % invasion were more likely to express IDO-1 (20 %) and PD-1/IDO-1 (1/5 %). Ultimately, the effect of IDO-1, PD-1 and PD-L1 on the clinical profile may be less important than its potential use as a immunotherapeutic
Like
Comment
Share
